Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 3, 2010, Pages

  Guellich, Aziz ^a,b   Gao, Shumin ^a   Hong, Chull ^a   Yan, Lin ^a   Wagner, Thomas E ^c   Dhar, Sunil K ^d   Ghaleh, Bijan ^b   Hittinger, Luc ^b   Iwatsubo, Kosaku ^a   Ishikawa, Yoshihiro ^a   Vatner, Stephen F ^a   Vatner, Dorothy E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c GREENVILLE HOSPITAL SYSTEM   (United States)

^d NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Apoptosis; Cardiac function; Hypertrophy; Transgenic; Transverse aortic constriction

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 6; FORSKOLIN; UNCLASSIFIED DRUG; ADENYLYL CYCLASE 6; ISOPRENALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CONTRACTILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; ANALYSIS OF VARIANCE; ANIMAL; APOPTOSIS; DRUG EFFECTS; ECHOCARDIOGRAPHY; GENETICS; HEART; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART RATE; HEART VENTRICLE; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ADENYLATE CYCLASE; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; ECHOCARDIOGRAPHY; FORSKOLIN; HEART; HEART RATE; HEART VENTRICLES; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; ISOPROTERENOL; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIUM; STRESS, PHYSIOLOGICAL; VENTRICULAR DYSFUNCTION, LEFT; COLFORSIN;

EID: 77955702308     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00148.2010     Document Type: Article

References (27)

1. Beazely MA, Watts VJ. Regulatory properties of adenylate cyclases type 5 and 6: a progress report. Eur J Pharmacol 535: 1-12, 2006.
2. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000. (Pubitemid 30080872)
3. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064, 1999.
4. Gao MH, Bayat H, Roth DM, Yao Zhou J, Drumm J, Burhan J, Hammond HK. Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function. Cardiovasc Res 56: 197-204, 2002.
5. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, Anzai T, Dalton N, Hammond HK. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 99: 1618-1622, 1999.
6. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41: 145-174, 2001. (Pubitemid 32385886)
7. Hu CL, Chandra R, Ge H, Pain J, Yan L, Babu G, Depre C, Iwatsubo K, Ishikawa Y, Sadoshima J, Vatner SF, Vatner DE. Adenylyl cyclase type 5 protein expression during cardiac development and stress. Am J Physiol Heart Circ Physiol 297: H1776-H1782, 2009.
8. Ihnatovych I, Novotny J, Haugvicova R, Bourova L, Mares P, Svoboda P. Ontogenetic development of the G protein-mediated adenylyl cyclase signalling in rat brain. Brain Res Dev Brain Res 133: 69-75, 2002. (Pubitemid 34146500)
9. sα overexpression. Am J Physiol Heart Circ Physiol 272: H585-H589, 1997.
10. Javed U, Deedwania PC. β-Adrenergic blockers for chronic heart failure. Cardiol Rev 17: 287-292, 2009.
11. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977-2016, 2009.
12. Lai NC, Tang T, Gao MH, Saito M, Takahashi T, Roth DM, Hammond HK. Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol 51: 1490-1497, 2008.
13. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101: 1707-1714, 2000.
14. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740, 1999.
15. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE, Sadoshima J, Vatner SF, Ishikawa Y. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100: 9986-9990, 2003.
16. Okumura S, Vatner DE, Kurotani R, Bai Y, Gao S, Yuan Z, Iwatsubo K, Ulucan C, Kawabe J, Ghosh K, Vatner SF, Ishikawa Y. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 116: 1776-1783, 2007.
17. Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, Ander A, Hammond HK. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105: 1989-1994, 2002.
18. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, Zhou JY, Zhu J, Entrikin D, Hammond HK. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99: 3099-3102, 1999.
19. Roubin GS, Choong CY, Devenish-Meares S, Sadick NN, Fletcher PJ, Kelly DT, Harris PJ. β-Adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. Circulation 69: 955-962, 1984. (Pubitemid 14137292)
20. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
21. Scarpace PJ, Matheny M, Tumer N. Myocardial adenylyl cyclase type V and VI mRNA: differential regulation with age. J Cardiovasc Pharmacol 27: 86-90, 1996.
22. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific regulation of the α-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 266: 24613-24620, 1991.
23. Takahashi T, Tang T, Lai NC, Roth DM, Rebolledo B, Saito M, Lew WY, Clopton P, Hammond HK. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 114: 388-396, 2006.
24. Tang T, Gao MH, Lai NC, Firth AL, Takahashi T, Guo T, Yuan JX, Roth DM, Hammond HK. Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation 117: 61-69, 2008.
25. Tang T, Gao MH, Roth DM, Guo T, Hammond HK. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol Heart Circ Physiol 287: H1906-H1912, 2004. (Pubitemid 39430724)
26. Tang T, Lai NC, Hammond HK, Roth DM, Yang Y, Guo T, Gao MH. Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice. J Am Coll Cardiol 55: 1476-1486.
27. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, Vatner SF. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130: 247-258, 2007.